Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults

Yuanyuan Zhang(Wuhan No.1 Hospital), Xianhui Qin(Nanfang Hospital), Chun Zhou(Nanfang Hospital), Yun Song(Novem (Netherlands)), Xiping Xu(Johns Hopkins University), Min Liang(Nanchang University), Di Xie(Xuzhou Medical College), Yong Huo(Sun Yat-sen University), Binyan Wang(Brigham and Women's Hospital), Yan Zhang(Yukhnovskii Institute for Condensed Matter Physics of the National Academy of Sciences of Ukraine), Xiaobin Wang(Fujian University of Traditional Chinese Medicine), Jianping Li(Binzhou Medical University), Fan Fan Hou(Southern Medical University)
Cardiovascular Diabetology
October 24, 2020
10.1186/s12933-020-01161-x
Cited by 36

Related Papers

Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
|The Lancet|2019|609
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
|The Lancet Diabetes & Endocrinology|2019|372